UNIVERSITY OF MICHIGAN

The BMJ investigation reveals data reporting issues in the PLATO trial, which supported ticagrelor's approval. FDA initially rejected due to higher US deaths, but later approved. Subsequent studies failed to replicate PLATO's positive results, raising questions about its validity and ticagrelor's guidelines.

Ticagrelor's efficacy over clopidogrel is questioned as post-licensure studies show similar results with increased bleeding and dyspnoea. FDA approved ticagrelor despite objections from scientific review staff, leading to ongoing controversy over PLATO trial data reliability.

Merck's PAH medication Winrevair (sotatercept) showed significant reduction in morbidity and mortality risk in advanced PAH patients, leading to early conclusion of ZENITH trial. The therapy, approved by FDA in 2024, aims to increase exercise capacity and reduce clinical worsening events, with plans to submit ZENITH data for potential indication expansion.

Dr. Tobias Nordström discussed prostate cancer screening with biomarkers and MRI at the 2024 SUO annual meeting, highlighting studies showing reduced mortality with PSA screening and the potential of biomarker tests like Stockholm3 to improve detection and reduce unnecessary procedures.

Kyle Cuneo, M.D., named associate director for clinical research and John Magenau, M.D., appointed assistant director at University of Michigan Rogel Cancer Center. They will collaborate to establish processes and infrastructure for cancer-focused clinical research, enhancing trial portfolios and addressing gaps in expertise.

A Michigan Medicine trial found no significant association between adenotonsillectomy and undesirable weight gain in children with mild sleep-disordered breathing, challenging the long-held belief that the surgery leads to weight gain.

Bioethicists from the NIH Pragmatic Trials Collaboratory recommend sharing aggregate results from pragmatic clinical trials with participants, emphasizing early planning and healthcare system partnerships for effective disclosure.

PDS Biotechnology announces a Key Opinion Leader event on Dec 17, 2024, to discuss HPV16-positive HNSCC and the VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab. Panelists include Dr. Francis Worden and Dr. Kevin Harrington, moderated by Dr. Kirk Shepard.

Roswell Park CEO Candace Johnson introduces Michael Wong as the center's first Physician in Chief, aiming to enhance patient care and outcomes. Wong, a former MD Anderson Cancer Center professor, will lead clinical teams and focus on improving care delivery.

New York mum Kait Handler, 40, gave her clinically obese 12-year-old daughter Birdie semaglutide to prevent obesity. Birdie lost weight and experienced mild nausea as a side effect. The drug use among children aged 12-15 has increased significantly.